PF-00610355

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
PF-00610355
Accession Number
DB11871
Type
Small Molecule
Groups
Investigational
Description

PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
PF - 00610355 / PF-610355
Categories
UNII
ZH5SMU97AJ
CAS number
862541-45-5
Weight
Average: 617.76
Monoisotopic: 617.255957162
Chemical Formula
C34H39N3O6S
InChI Key
YPHDIMUXXABSSO-YTTGMZPUSA-N
InChI
InChI=1S/C34H39N3O6S/c1-34(2,36-22-32(40)28-12-15-31(39)30(19-28)37-44(3,42)43)20-24-7-4-6-23(16-24)18-33(41)35-21-25-8-5-9-27(17-25)26-10-13-29(38)14-11-26/h4-17,19,32,36-40H,18,20-22H2,1-3H3,(H,35,41)/t32-/m0/s1
IUPAC Name
2-[3-(2-{[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonamidophenyl)ethyl]amino}-2-methylpropyl)phenyl]-N-({4'-hydroxy-[1,1'-biphenyl]-3-yl}methyl)acetamide
SMILES
CC(C)(CC1=CC=CC(CC(=O)NCC2=CC=CC(=C2)C2=CC=C(O)C=C2)=C1)NC[C@H](O)C1=CC=C(O)C(NS(C)(=O)=O)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with PF-00610355.
AcebutololThe therapeutic efficacy of PF-00610355 can be decreased when used in combination with Acebutolol.
AlclometasoneThe risk or severity of hypokalemia can be increased when Alclometasone is combined with PF-00610355.
AlfuzosinThe therapeutic efficacy of PF-00610355 can be decreased when used in combination with Alfuzosin.
AlprenololAlprenolol may decrease the bronchodilatory activities of PF-00610355.
AmcinonideThe risk or severity of hypokalemia can be increased when Amcinonide is combined with PF-00610355.
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with PF-00610355.
AmitriptylineThe therapeutic efficacy of PF-00610355 can be decreased when used in combination with Amitriptyline.
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with PF-00610355.
AmoxapineThe therapeutic efficacy of PF-00610355 can be decreased when used in combination with Amoxapine.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11505444
PubChem Substance
347828208
ChemSpider
9680243
BindingDB
50326537
ChEMBL
CHEMBL1240967

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentChronic Lung Diseases / Moxifloxacin / Pulmonary Diseases1
2CompletedTreatmentChronic Lung Diseases / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentPulmonary Disease, Chronic Obstructive1
2WithdrawnTreatmentBronchial Asthma / Bronchial Diseases / Lung Diseases, Obstructive / Respiratory Tract Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00121 mg/mLALOGPS
logP4.38ALOGPS
logP3.11ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)7.85ChemAxon
pKa (Strongest Basic)9.58ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area147.99 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity172.11 m3·mol-1ChemAxon
Polarizability67.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Amphetamines and derivatives / Phenylacetamides / Sulfanilides / Phenylpropanes / 1-hydroxy-2-unsubstituted benzenoids / Aralkylamines / Organosulfonamides / Organic sulfonamides / Aminosulfonyl compounds / 1,2-aminoalcohols
show 8 more
Substituents
Biphenyl / Sulfanilide / Phenylacetamide / Amphetamine or derivatives / Phenylpropane / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Organosulfonic acid amide / Organic sulfonic acid amide
show 24 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:56 / Updated on October 01, 2018 15:06